4.4 Article

Augmenting the potency of third-line antibiotics with Berberis aristata: In vitro synergistic activity against carbapenem-resistant Escherichia coli

期刊

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.jgar.2016.01.015

关键词

Berberis aristata; Synergistic effects; New Delhi metallo-beta-lactamase-1 (NDM-1); Escherichia coli; Fractional inhibitory concentration index; Multidrug resistance

资金

  1. Institute of Nuclear Medicine and Allied Sciences (INMAS, New Delhi, India)
  2. National Centre for Disease Control (NCDC, New Delhi, India)
  3. ISF College of Pharmacy (Moga, India)

向作者/读者索取更多资源

The aim of this study was to analyse the in vitro synergistic antibacterial potential of an aquoethanolic extract of the stem bark of Berberis aristata (PTRC-2111-A) with third-line antibiotics against carbapenem-resistant Escherichia coli. PTRC-2111-A was prepared and was characterised using phytochemical-and bioactivity-based fingerprinting. Fourier transform infrared spectroscopy (FTIR) and liquid chromatography-mass spectrometry (LC-MS) analyses were performed, and superoxide and hydroxyl scavenging activities were assessed in conjunction with in vitro antimicrobial efficacy testing against the test micro-organism. Analysis of drug combinations of PTRC-2111-A and third-line antibiotics was performed using CompuSyn software. PTRC-2111-A from B. aristata was found to have seven common functional groups in comparison with the pre-identified marker compound quercetin, and phytochemical quantitation analysis revealed the presence of 25.44% alkaloids. Moreover, PTRC-2111- A was found to contain isoquinoline alkaloids, namely berbamine, berberine, reticuline, jatrorrhizine, palmatine and piperazine, as elucidated in the LC-MS analysis. Analysis of combinations of PTRC -2111-A and antibiotics revealed synergistic behaviour [fractional inhibitory concentration index (FICI) < 1] with colistin, tigecycline and amoxicillin/ clavulanate potassium (Augmentin (R)), whereas antagonism (FICI > 1) was seen with ertapenem and meropenem. (C) 2016 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据